Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Cardiology - Volume 154, Issue 3, 9 February 2012, Pages 341-344

Christodoulos Stefanadis, Andreas Synetos, Dimitris Tousoulis, Eleftherios Tsiamis, Archontoula Michelongona, Flora Zagouri, Aristotle Bamias, Meletios Athanasios Dimopoulos, Stella Kyvelou, Ioannis Kapelakis, Konstantinos Toutouzas,